YU87501A - Farmaceutski kompleksi - Google Patents

Farmaceutski kompleksi

Info

Publication number
YU87501A
YU87501A YU87501A YUP87501A YU87501A YU 87501 A YU87501 A YU 87501A YU 87501 A YU87501 A YU 87501A YU P87501 A YUP87501 A YU P87501A YU 87501 A YU87501 A YU 87501A
Authority
YU
Yugoslavia
Prior art keywords
complex
pharmaceutical complex
pharmaceutical
sulfobutylether
eletriptan
Prior art date
Application number
YU87501A
Other languages
English (en)
Inventor
Anne Billote
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU87501A publication Critical patent/YU87501A/sh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na kompleks eletriptana i sulfobutileter-beta-ciklodekstrina, ili na njegovu farmaceutski prihvatljivu so, i na postupke za dobijanje farmaceutskih formulacija, i na upotrebe takvog kompleksa.
YU87501A 1999-06-29 2000-06-02 Farmaceutski kompleksi YU87501A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
YU87501A true YU87501A (sh) 2004-05-12

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
YU87501A YU87501A (sh) 1999-06-29 2000-06-02 Farmaceutski kompleksi

Country Status (44)

Country Link
US (2) US6713461B1 (sh)
EP (1) EP1189640B1 (sh)
JP (2) JP4454900B2 (sh)
KR (1) KR20020015067A (sh)
CN (1) CN1198654C (sh)
AP (1) AP2001002369A0 (sh)
AR (1) AR033337A1 (sh)
AT (1) ATE290884T1 (sh)
AU (1) AU770169B2 (sh)
BG (1) BG106151A (sh)
BR (1) BR0011845A (sh)
CA (1) CA2376847C (sh)
CO (1) CO5170494A1 (sh)
CZ (1) CZ20014572A3 (sh)
DE (1) DE60018744T2 (sh)
DZ (1) DZ3320A1 (sh)
EA (1) EA003908B1 (sh)
EC (1) ECSP003551A (sh)
EE (1) EE200100697A (sh)
ES (1) ES2235879T3 (sh)
GB (1) GB9915231D0 (sh)
GE (1) GEP20043377B (sh)
GT (1) GT200000102A (sh)
HR (1) HRP20010951A2 (sh)
HU (1) HUP0201629A3 (sh)
IL (1) IL146341A0 (sh)
IS (1) IS6163A (sh)
MA (1) MA26801A1 (sh)
MX (1) MXPA01013274A (sh)
NO (1) NO20016430L (sh)
NZ (1) NZ515235A (sh)
OA (1) OA11964A (sh)
PA (1) PA8496801A1 (sh)
PE (1) PE20010346A1 (sh)
PL (1) PL352902A1 (sh)
SK (1) SK18932001A3 (sh)
SV (1) SV2002000112A (sh)
TN (1) TNSN00142A1 (sh)
TR (1) TR200103827T2 (sh)
UA (1) UA66932C2 (sh)
UY (1) UY26224A1 (sh)
WO (1) WO2001000243A1 (sh)
YU (1) YU87501A (sh)
ZA (1) ZA200110454B (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
PL212428B1 (pl) * 2002-08-20 2012-09-28 Bristol Myers Squibb Co Kompleks aripiprazolu, preparat farmaceutyczny zawierajacy ten kompleks i jego zastosowanie
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
WO2019143925A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
DE69127468T2 (de) 1990-10-15 1998-01-02 Pfizer Indolderivate
RU2143896C1 (ru) 1993-03-05 2000-01-10 Хексаль Аг Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
PL181064B1 (pl) 1994-03-07 2001-05-31 Dendritech Inc Kompleks polimeru typu gęstej gwiazdy, kompozycja do przenoszenia materiału genetycznego i sposób wytwarzania kompleksu polimeru typu gęstej gwiazdy
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
WO1998002187A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
DZ2549A1 (fr) 1997-07-03 2003-02-08 Pfizer Prod Inc Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan.
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
TR200103827T2 (tr) 2002-05-21
CO5170494A1 (es) 2002-06-27
AR033337A1 (es) 2003-12-17
JP2003503364A (ja) 2003-01-28
IL146341A0 (en) 2002-07-25
CN1359303A (zh) 2002-07-17
AU4774100A (en) 2001-01-31
SV2002000112A (es) 2002-02-05
TNSN00142A1 (fr) 2005-11-10
DE60018744T2 (de) 2006-05-18
DZ3320A1 (fr) 2001-01-04
GT200000102A (es) 2001-12-14
DE60018744D1 (de) 2005-04-21
CA2376847A1 (en) 2001-01-04
HUP0201629A3 (en) 2003-11-28
UA66932C2 (en) 2004-06-15
PA8496801A1 (es) 2002-02-21
MXPA01013274A (es) 2002-06-04
BG106151A (en) 2002-05-31
US6713461B1 (en) 2004-03-30
CN1198654C (zh) 2005-04-27
JP2006257091A (ja) 2006-09-28
CZ20014572A3 (cs) 2002-08-14
ES2235879T3 (es) 2005-07-16
HUP0201629A2 (hu) 2003-03-28
ECSP003551A (es) 2002-01-25
OA11964A (en) 2006-04-17
MA26801A1 (fr) 2004-12-20
GB9915231D0 (en) 1999-09-01
HRP20010951A2 (en) 2005-04-30
NO20016430L (no) 2002-02-26
EP1189640B1 (en) 2005-03-16
ZA200110454B (en) 2002-12-20
KR20020015067A (ko) 2002-02-27
ATE290884T1 (de) 2005-04-15
PE20010346A1 (es) 2001-03-26
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
CA2376847C (en) 2007-09-25
WO2001000243A1 (en) 2001-01-04
AU770169B2 (en) 2004-02-12
GEP20043377B (en) 2004-04-13
EE200100697A (et) 2003-02-17
EA200101106A1 (ru) 2002-06-27
NO20016430D0 (no) 2001-12-28
PL352902A1 (en) 2003-09-22
AP2001002369A0 (en) 2001-12-31
EP1189640A1 (en) 2002-03-27
US20040186076A1 (en) 2004-09-23
BR0011845A (pt) 2002-03-05
NZ515235A (en) 2003-08-29
UY26224A1 (es) 2001-01-31
JP4454900B2 (ja) 2010-04-21
SK18932001A3 (sk) 2002-09-10

Similar Documents

Publication Publication Date Title
SE9504661D0 (sv) New compounds
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DE69907977D1 (de) Pyrrolobenzodiazepine
EA199900373A2 (ru) Фармацевтические композиции
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
EE9900539A (et) Uued ühendid
IS5198A (is) Ný efnasambönd
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
DE69705300T2 (de) Cyclopropylalkansäurederivate
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
YU87501A (sh) Farmaceutski kompleksi
DE60128100D1 (de) Analgetisches arzneimittel
DE69819539D1 (de) Antithrombotische mittel
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
SE9802209D0 (sv) Novel compounds
SE9504662D0 (sv) New compounds
SE0001916D0 (sv) Novel formulation
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli